Roche Holding AG (ROG.VX)
235.70CHF
11:32am EDT
CHF1.10 (+0.47%)
CHF234.60
CHF235.10
CHF236.00
CHF231.90
1,005,895
1,538,690
CHF258.60
CHF164.00
ROG.VX
About
Overall
| Beta: | 0.90 |
| Market Cap (Mil.): | CHF202,261.20 |
| Shares Outstanding (Mil.): | 862.56 |
| Dividend: | 7.35 |
| Yield (%): | 3.13 |
Financials
| ROG.VX | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 21.04 | 32.01 | 32.18 |
| EPS (TTM): | 11.15 | -- | -- |
| ROI: | 22.90 | 19.61 | 18.91 |
| ROE: | 71.75 | 20.45 | 19.87 |
Roche buys U.S. blood-testing firm for initial $220 million
ZURICH - - Swiss drugmaker Roche Holding AG is buying Constitution Medical Investors (CMI), the U.S. developer of a testing system for blood diseases like anemia and leukemia, for an upfront $220 million, plus further contingent payments.
UPDATE 1-Roche buys U.S. blood-testing firm for initial $220 mln
ZURICH, July 2 - - Swiss drugmaker Roche Holding AG is buying Constitution Medical Investors (CMI), the U.S. developer of a testing system for blood diseases like anaemia and leukaemia, for an upfront $220 million, plus further contingent payments.
Swiss stocks - Factors to watch on June 25
ZURICH, June 25 - Swiss stocks were expected to open higher on Monday, though a drop in Asian stocks amid worries that tight liquidity may threaten China's economic growth could dampen sentiment.
Indian drugmaker Intas to sell generic Xeloda in US
June 24 - Privately held Indian drugmaker Intas Pharmaceuticals Ltd said it signed an agreement with Roche Holding AG to sell a generic version of the Swiss drugmaker's chemotherapy drug Xeloda.
Roche drug approved in Japan for treatment of brain cancer
ZURICH - Japan's health ministry has approved drug Avastin for the treatment of aggressive brain cancer in Japan, Swiss pharmaceuticals company Roche said on Monday.
Roche drug approved in Japan for treatment of brain cancer
ZURICH, June 17 - Japan's health ministry has approved drug Avastin for the treatment of aggressive brain cancer in Japan, Swiss pharmaceuticals company Roche said on Monday.
Roche drug gets EU nod to treat arthritis in children
ZURICH - Swiss pharmaceuticals company Roche Holding AG said on Monday the European Medicines Agency has approved its rheumatoid arthritis drug RoActemra to treat children aged two or older suffering from a rare form of childhood arthritis.
Roche drug gets EU nod to treat arthritis in children
ZURICH, June 10 - Swiss pharmaceuticals company Roche Holding AG said on Monday the European Medicines Agency has approved its rheumatoid arthritis drug RoActemra to treat children aged two or older suffering from a rare form of childhood arthritis.
BRIEF-EU approves Roche's Roactemra for children's arthritis
ZURICH, June 10 - Roche Holding AG : * Media release: roche's roactemra approved in EU to treat children with rare
STOCKS NEWS EUROPE-Roche down on negative Avastin data
Shares in Swiss-based Roche fall 3.4 percent to lead the European healthcare index lower after data showed its blockbuster cancer drug Avastin had failed to prolong survival for patients suffering from a type of brain tumour.
Earnings vs. 
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Validea
|
$12.00
|
|
Provider: Datamonitor
|
$175.00
|
|
Provider: Thomson Reuters StreetEvents
|
$75.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
